Patrick Matthiessen, MD
Neurology · la Grange, KYNPI 1306833124
Payments from drug & device makers
Across 613 payments — averaging $125.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$38K
- Eisai Inc.$32K
- Lilly USA, LLC$1K
- UCB, Inc.$777
- Novartis$614
- Teva Pharmaceuticals USA, Inc.$612
- plus $5K from 32 others
What the payments were for
- Consulting fees$10,01313%
- Speaking & faculty fees$54,25170%
- Travel & lodging$1,6882%
- Food & beverage$10,76414%
- Education$4651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 180 | $37,766 |
| Eisai Inc. | 111 | $31,659 |
| Lilly USA, LLC | 38 | $1,149 |
| UCB, Inc. | 45 | $777 |
| Novartis | 22 | $614 |
| Teva Pharmaceuticals USA, Inc. | 11 | $612 |
| Vanda Pharmaceuticals Inc. | 16 | $439 |
| Biogen | 11 | $317 |
| Catalyst Pharmaceuticals, Inc. | 14 | $283 |
| EMD Serono, Inc. | 7 | $264 |
| SK Life Science, Inc. | 17 | $252 |
| Livanova USA, Inc. | 4 | $234 |
| Pfizer | 10 | $224 |
| Otsuka America Pharmaceutical, Inc. | 7 | $196 |
| Genentech USA, Inc. | 8 | $195 |
| Johnson & Johnson | 6 | $191 |
| Argenx US, Inc. | 11 | $188 |
| Amneal Pharmaceuticals LLC | 10 | $163 |
| TG Therapeutics, Inc. | 8 | $153 |
| Acadia Pharmaceuticals Inc | 9 | $149 |
| Lundbeck LLC | 8 | $136 |
| AstraZeneca | 8 | $136 |
| Sunovion Pharmaceuticals Inc. | 16 | $130 |
| Novo Nordisk | 1 | $120 |
| Silk Road Medical, Inc. | 1 | $119 |
| Amgen | 1 | $96 |
| Jazz Pharmaceuticals Inc. | 4 | $95 |
| Neurelis, Inc. | 5 | $83 |
| CSL Behring | 4 | $82 |
| Sumitomo Pharma America, Inc. | 4 | $63 |
| Impel Pharmaceuticals Inc. | 4 | $62 |
| Alnylam Pharmaceuticals Inc. | 3 | $53 |
| Neurocrine Biosciences, Inc. | 2 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Impel Pharmaceuticals LLC | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$36,061
- Leqembi$30,714
- QULIPTA$6,406
- MAYZENT$236
- VNS - Sentiva$189
- TYSABRI$150
- Mavenclad$124
- KISUNLA$120
- Ponvory$120
- ENROUTE Transcarotid Neuroprotection System$119
- ENROUTE Transcarotid Stent$119
- Nayzilam$102
- XCOPRI$100
How this compares
$77,182 in reported general payments places this provider in the 85th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 13 | $187,307 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 15 | $185,644 |
| UbrelvyUbrogepant | 92 | $133,764 |
| NuplazidPimavanserin Tartrate | 24 | $114,471 |
| AubagioTeriflunomide | 12 | $108,211 |
| Nurtec OdtRimegepant Sulfate | 49 | $96,945 |
| Dimethyl Fumarate | 17 | $82,494 |
| Aimovig AutoinjectorErenumab-Aooe | 33 | $28,181 |
| RexultiBrexpiprazole | 16 | $21,209 |
| QuliptaAtogepant | 16 | $17,379 |
| NayzilamMidazolam | 19 | $14,935 |
| RytaryCarbidopa/Levodopa | 17 | $14,668 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 19 | $13,936 |
| Lacosamide | 76 | $7,474 |
| Memantine Hcl | 234 | $6,683 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $612 | $187,30713 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $42 | $185,64415 claims |
| AbbVieUbrelvy, Qulipta | $37,766 | $151,143108 claims |
| Acadia Pharmaceuticals IncNuplazid | $149 | $114,47124 claims |
| PfizerNurtec Odt | $224 | $96,94549 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $196 | $21,20916 claims |
| Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil | $163 | $15,67443 claims |
| UCB, Inc.Nayzilam | $777 | $14,93519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 210 neurology providers in Kentucky.
Other neurology in la Grange
- James MaynardFort Thomas$12.4M
- Gregory JichaLexington$7.1M
- Irene LitvanLouisville$2.7M
- Jenny FengLouisville$2M
- James WinkleyLexington$1.9M
- John SlevinLexington$984K
- Nicole EvermanLexington$834K
- Geeta GaneshLouisville$765K
- Zabeen MahuwalaLexington$694K
- Peter HederaLouisville$422K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.